INMB (INmune Bio) Tariff Resilience Score: 9/10 (As of Jun. 29, 2026)


INMB INmune Bio Inc INMB
52 GF Score
Price $1.62
GF Value $1.83
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is INmune Bio Tariff Resilience Score?

INmune Bio INMB +14.08% 52 Tariff Resilience Score is 9 as of Jun. 29, 2026. GuruFocus rates INMB with a GF Score™ of 52/100 and a GF Value™ of $1.83 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 1,375 Biotechnology companies, INmune Bio ranks better than 99.93% on this metric.

INmune Bio has the Tariff Resilience Score of 9, which implies that the company might have Highly Resilient.

INmune Bio has INmune Bio Inc is highly resilient to tariffs due to its domestic operations and minimal reliance on international suppliers. The company has strong pricing power and benefits from industry-specific exemptions.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes INmune Bio might have Highly Resilient.

INmune Bio  (NAS:INMB) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

INmune Bio Tariff Resilience Score Related Terms

INMB vs GRCE, NTRB, ABVC: Tariff Resilience Score Comparison

For the Biotechnology subindustry, INmune Bio's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

INmune Bio Tariff Resilience Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, INmune Bio's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where INmune Bio's Tariff Resilience Score falls into.


INMB
52GF Score
INmune Bio Inc INMB
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Tariff Resilience Score of 9 mean?
INmune Bio (INMB) has a Tariff Resilience Score of 9 as of Jun. 29, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, INmune Bio ranks #1 out of 1375 companies in the Biotechnology industry, placing it in the top 0.099999999999994%.
Is INmune Bio's Tariff Resilience Score too high?
INmune Bio's current Tariff Resilience Score is 9. The Biotechnology industry median Tariff Resilience Score is 4.00. INmune Bio's value of 9 is 125% above this industry median. Based on the distribution chart, INmune Bio ranks #1 out of 1375 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, INmune Bio has a GF Score™ of 52/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does INmune Bio's Tariff Resilience Score compare to GRCE and NTRB?
According to the Biotechnology industry distribution chart, INmune Bio ranks #1 out of 1375 companies for Tariff Resilience Score. This places INmune Bio in the top 0% of its industry — outperforming the majority of peers. The industry median Tariff Resilience Score is 4.00. INmune Bio's value of 9 is 125% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Biotechnology company?
The median Tariff Resilience Score among Biotechnology companies is 4.00, based on 1,375 companies in the industry. Companies in the top quartile (top 25%) have a Tariff Resilience Score significantly above this median, while those in the bottom quartile fall well below. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. INmune Bio's current Tariff Resilience Score of 9 is 125% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. For the Biotechnology industry, the median Tariff Resilience Score is 4.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. INmune Bio's current Tariff Resilience Score is 9. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is INmune Bio stock overvalued right now?
Based on GuruFocus' analysis, INmune Bio (INMB) is currently considered Modestly Undervalued. The stock's GF Value™ is $1.83, compared to a current price of $1.62 — trading 11.5% below its estimated fair value. The current Tariff Resilience Score is 9 and 125% above the Biotechnology industry median of 4.00. INmune Bio's overall GF Score™ is 52/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For INmune Bio (INMB), the current Tariff Resilience Score is 9 as of Jun. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is INmune Bio (INMB) Overvalued in 2026?

Based on GuruFocus' analysis, INmune Bio stock appears to be undervalued. The current stock price of $1.62 is trading 11.5% below its estimated GF Value™ of $1.83. GuruFocus considers INmune Bio to be Modestly Undervalued.

Key valuation signals for INMB:

  • Tariff Resilience Score: 9
  • GF Value™: $1.83 vs. price of $1.62 (11.5% below fair value)
  • GF Score™: 52/100 with 4 warning signs
  • Industry Position: 125% above the Biotechnology median (#1 of 1375)

No single metric tells the full story. See the INMB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

INmune Bio Business Description

Address 225 NE Mizner Boulevard, Suite 640, Boca Raton, FL, USA, 33432
INmune Bio Inc is a clinical stage biotechnology pharmaceutical company focused on developing and commercializing its product candidates to treat diseases where inflammation and immunology cause a dysfunctional immune system contributing to disease. The company's pipeline products include INKmune, XPro1595, and others. It has three product platforms; The CORDStrom product platform, The DN-TNF product platform, and The Natural Killer Cell Priming Platform.
52GF Score

Get the complete analysis for INMB

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.62
Price
$1.83
GF Value